Preparation method of medicinal glyceryl monoricinoleate
The preparation of pharmaceutical-grade monoricinoleic acid glyceride by hydroxyl protection method and molecular distillation technology solves the problems of high purification difficulty and unqualified product quality in the existing technology, and realizes the production of pharmaceutical-grade monoricinoleic acid glyceride with high purity and high yield.
Patent Information
- Application Number
- CN202411153693.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-26
AI Technical Summary
In the existing technology, the purification of ricinoleate monoester is difficult, with many byproducts, low purification yield, and product quality that does not meet pharmaceutical standards. In particular, the content of ricinoleate monoester is low and the content of impurities is high, making it difficult to meet pharmaceutical requirements.
Pharmaceutical grade monoricinoleic acid glyceride was prepared using a hydroxyl protection method. The exposed hydroxyl groups of ricinoleic acid were protected with tert-butyldimethylchlorosilane, followed by esterification with glycerol. Finally, the protecting group was removed with tetrabutylammonium fluoride. The experimental conditions and parameters were precisely controlled by combining solid acid catalysts and molecular distillation techniques.
It significantly reduces the formation of byproducts, improves purification yield, and ensures that the product quality meets pharmaceutical standards. It has a high content of monoricinoleic acid glyceride, low impurity content, and excellent acid value, moisture content, and other indicators, making it suitable for industrial production.
Smart Images

Figure CN119019253A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of pharmaceuticals, and particularly relates to a method for preparing medicinal monoricinoleyl glyceride. Background Art
[0002] Monoricinoleic acid glyceride is a mixture of monoglyceride, diglyceride and triglyceride of ricinoleic acid. It is a colorless to yellow-brown liquid or waxy solid. It is soluble in chloroform or petroleum ether, almost insoluble in water or ethanol, and has a high viscosity. Monoricinoleic acid glyceride is widely used in industry and pharmacy. In industry, it can be used as a lubricant, thickener and emulsifier, and is commonly used in the automotive industry, paper and textile industry. In the pharmaceutical field, medicinal monoricinoleic acid glyceride is a pharmaceutical excipient that can be used for topical, sublingual and other administrations. It can be used as an oily carrier, such as a carrier for some topical lotions, to produce local effects and achieve the therapeutic effects of removing dandruff, seborrheic dermatitis of the scalp, and tinea versicolor.
[0003] At present, monoricinoleic acid glyceride is generally esterified by ricinoleic acid and glycerol as raw materials under the action of a catalyst. Since ricinoleic acid contains exposed hydroxyl groups, it is easy to undergo intermolecular esterification reactions, resulting in more by-products, and similar polarity, which makes purification difficult and has a low yield. The quality of commercially available monoricinoleic acid glyceride products is poor, and the content of monoricinoleic acid glyceride is only about 30%. Impurities are mainly diglycerides, triglycerides, and intermolecular esterification products. At the same time, its free glycerol content, acid value, and moisture content are all high, making it difficult to meet medicinal needs. Therefore, in order to improve the quality of monoricinoleic acid glyceride products and meet medicinal needs, it is urgent to develop a preparation method for medicinal monoricinoleic acid glyceride with few by-products, low impurity content, high content of monoricinoleic acid glyceride, excellent quality, high yield, low production cost, and suitable for industrial production. Summary of the invention
[0004] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a method for preparing medicinal monoricinoleyl glyceride which has simple process, safe operation, low cost and meets the product quality standards.
[0005] The technical solution of the present invention is summarized as follows:
[0006] The preparation method of medicinal monoricinoleyl glyceride comprises the following steps:
[0007] (1) methyl ricinoleate (I), dichloromethane and triethylamine are added to a reaction vessel in a mass ratio of 1:6.5-8:0.4-0.7, and stirred evenly under a nitrogen atmosphere; the temperature is lowered to 0° C., and a 7M dichloromethane solution of tert-butyldimethylsilyl chloride is added dropwise under stirring, the temperature is raised to 25-40° C., and the reaction is carried out for 3-5 hours to obtain a reaction solution containing the intermediate (II), wherein the molar ratio of methyl ricinoleate to tert-butyldimethylsilyl chloride is 1:1.1-1.6;
[0008] (2) filtering the reaction solution containing the intermediate (II), concentrating the filtrate under reduced pressure until the mass of the concentrate is 2.5 to 4 times the mass of ricinoleic acid methyl ester, passing through a 100 to 200 mesh silica gel column, eluting with dichloromethane / methanol in a volume ratio of 10 / 1 as the mobile phase, spotting on a TLC plate, the developing solvent of the TLC plate being dichloromethane / methanol in a volume ratio of 6 / 1, collecting the eluate containing the intermediate (II), concentrating under reduced pressure, and drying to obtain the intermediate (II);
[0009] (3) Dissolve the intermediate (II) in methanol, add a 1M sodium hydroxide aqueous solution, wherein the molar ratio of the intermediate (II) to the sodium hydroxide is 1:1.3-2.0; heat to 40-60°C, react for 2-4 hours to obtain a sodium salt reaction solution containing the intermediate (III), and concentrate under reduced pressure to remove methanol; adjust the pH to 6.5-7.0 with dilute hydrochloric acid, add dichloromethane for extraction, collect and concentrate the dichloromethane extract, and dry to obtain the intermediate (III);
[0010] (4) adding glycerol and toluene in a mass ratio of 1:3.5-6 to a reaction vessel equipped with a water separator, adding a solid acid catalyst, evacuating the vessel, and heating the vessel until the pressure drops to ≤-0.09 MPa, adding a toluene solution of the intermediate (III) dropwise, and reacting the mixture for 4-7 hours to obtain a reaction solution containing the intermediate (IV), wherein the molar ratio of the intermediate (III) to glycerol is 1:1.05-1.7;
[0011] (5) the reaction solution containing the intermediate (IV) is decompressed to completely remove toluene, the concentrated solution is dissolved in a tetrahydrofuran solvent, stirred evenly, a 1M tetrabutylammonium fluoride tetrahydrofuran solution is added, the temperature is raised to 25-35° C. with stirring, and the reaction is performed for 2-4 hours to obtain a reaction solution containing monoricinoleylglycerol, wherein the molar ratio of the tetrabutylammonium fluoride to the intermediate (III) is 1.3-2.1:1; and the volume of the tetrahydrofuran solvent is 0.8-1.2 times the volume of the 1M tetrabutylammonium fluoride tetrahydrofuran solution;
[0012] (6) The reaction solution containing ricinoleyl glyceride is concentrated under reduced pressure to completely remove tetrahydrofuran, dissolved with a mixture of n-hexane / ethyl acetate in a volume ratio of 10 / 1, passed through a 100-200 mesh silica gel column, eluted with a mobile phase of n-hexane / ethyl acetate in a volume ratio of 8 / 1, applied to a TLC plate, wherein the developing solvent of the TLC plate is n-hexane / ethyl acetate in a volume ratio of 5 / 1, the eluate containing ricinoleyl glyceride is collected, and concentrated under reduced pressure to completely remove n-hexane / ethyl acetate to obtain a concentrated solution; the volume of the n-hexane / ethyl acetate mixture in a volume ratio of 10 / 1 is 1 / 15 to 1 / 10 of the volume of the tetrahydrofuran solvent described in step (5);
[0013] (7) passing the concentrated solution obtained in step (6) into a storage tank of a secondary molecular distillation device; setting the temperature of the secondary molecular distillation device to 145° C. to 190° C., and when the vacuum degree drops below 5 Pa, passing the concentrated solution into the cavity of the secondary molecular distillation device at a flow rate of 25 mL / min to 60 mL / min, performing molecular distillation, and collecting the heavy components to obtain medicinal monoricinoleyl glyceride (V);
[0014] The synthetic route is as follows:
[0015]
[0016] The TBSCl is the abbreviation of tert-butyldimethylchlorosilane; the OTBS is the abbreviation of tert-butyldimethylsiloxy; and the TBAF is the abbreviation of tetrabutylammonium fluoride.
[0017] Preferably, in step (1), the molar ratio of methyl ricinoleate to tert-butyldimethylchlorosilane is 1:1.25-1.4.
[0018] Preferably, the mass of the solid acid catalyst in step (4) is equivalent to 0.8% to 2.5% of the mass of the intermediate (III).
[0019] Preferably, the solid acid catalyst is anhydrous p-toluenesulfonic acid, solid acid catalyst No. 4 or T-62MP strong acid cation exchange resin.
[0020] Preferably, the molar ratio of the intermediate (III) to glycerol in step (4) is 1:1.2-1.5.
[0021] Preferably, the volume of the tetrahydrofuran solvent in step (5) is equal to the volume of a 1M tetrabutylammonium fluoride solution in tetrahydrofuran.
[0022] Preferably, the temperature of the secondary molecular distillation equipment in step (7) is set to 160°C to 180°C.
[0023] Advantages of the present invention:
[0024] 1. The present invention adopts a hydroxyl protection method to prepare medicinal monoricinoleic acid glyceride, that is, firstly protecting the exposed hydroxyl group of ricinoleic acid methyl ester with a protecting group, hydrolyzing and demethylating, then reacting with glycerol for esterification, and finally deprotecting. Compared with the traditional production process, this method can prevent the exposed hydroxyl group of ricinoleic acid from undergoing esterification, reduce the occurrence of by-products, greatly reduce the difficulty of purification, and improve the purification yield;
[0025] 2. The present invention uses tert-butyldimethylsilyl chloride as the hydroxyl protecting group, which is relatively stable under acidic conditions and is not easily deprotected. Tetrabutylammonium fluoride is used to remove the protecting group under mild conditions and with a fast reaction rate;
[0026] 3. The solid acid catalyst used in the present invention has high reaction activity, small dosage and simple post-treatment;
[0027] 4. Based on the precise control of experimental conditions and test parameters, the present invention obtains a monoricinoleylglycerol content of more than 94%, an acid value of less than 0.1, a peroxide value of less than 0.5, a free glycerin of less than 0.1%, a residue on ignition of less than 0.1%, and a moisture content of less than 0.1%, and the risk of oxidative rancidity is greatly reduced. The quality is excellent, and the quality indicators all meet the standards of pharmaceutical enterprises and meet the pharmaceutical needs;
[0028] 5. The production process used in the present invention is controllable, highly safe, has readily available raw materials, low production cost, high yield, is environmentally friendly and pollution-free, and is suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 For medicinal use of monoricinoleyl glyceride 1 H-NMR spectrum.
[0030] Figure 2 It is the HPLC spectrum of medicinal monoricinoleylglycerol. DETAILED DESCRIPTION
[0031] The present invention is further described in detail in the following examples, which should not be construed as limiting the claims of the present invention.
[0032] The catalyst used in the present invention is anhydrous p-toluenesulfonic acid (Shandong Xiya Chemical Co., Ltd.); solid acid catalyst No. 4 (Qinzhou Yamei Chemical Co., Ltd.); T-62MP strong acid cation exchange resin (Kohais (Beijing) Technology Co., Ltd.) as examples, but the present invention is not limited thereto.
[0033] The preparation method of the toluene solution of the intermediate (III) in each example is as follows: according to the proportion, 100 g of the intermediate (III) is added into 200 mL of toluene, and stirred to dissolve until it becomes clear.
[0034] Example 1
[0035] The preparation method of medicinal monoricinoleyl glyceride comprises the following steps:
[0036] (1) 500 g (1.6 mol) of methyl ricinoleate, 3250 g of dichloromethane, and 350 g of triethylamine were added to a reaction vessel in sequence, and stirred evenly under a nitrogen atmosphere; the temperature was lowered to 0° C., and a 7 M dichloromethane solution (251 mL, 1.76 mol) of tert-butyldimethylsilyl chloride was added dropwise under stirring; the temperature was raised to 25° C., and the reaction was carried out for 5 hours to obtain a reaction solution containing the intermediate (II);
[0037] (2) The reaction solution containing the intermediate (II) was filtered, and the filtrate was concentrated under reduced pressure until the mass of the concentrate was 2.5 times the mass of ricinoleic acid methyl ester (1250 g), and passed through a 100-200 mesh silica gel column, eluted with dichloromethane / methanol in a volume ratio of 10 / 1 as the mobile phase, and spotted on a TLC plate, the developing solvent of the TLC plate was dichloromethane / methanol in a volume ratio of 6 / 1, and the eluate containing the intermediate (II) was collected, and the eluate was concentrated under reduced pressure and dried to obtain 650.06 g of the intermediate (II);
[0038] (3) 650.06 g (1.52 mol) of intermediate (II) was dissolved in 3900.4 g of methanol, 1976 mL of 1 M sodium hydroxide aqueous solution was added, the temperature was raised to 60° C., and the reaction was carried out for 2 hours to obtain a sodium salt reaction solution containing intermediate (III). The methanol was removed by concentration under reduced pressure, the pH was adjusted to 6.5 with dilute hydrochloric acid, 3250.3 g of dichloromethane was added for extraction, the dichloromethane extract was collected and concentrated, and dried to obtain 597.84 g (1.45 mol) of intermediate (III);
[0039] (4) 227.24 g (2.47 mol) of glycerol and 795.34 g of toluene were sequentially added into a reaction vessel equipped with a water separator, and 14.95 g of solid acid catalyst No. 4 was added, and the mixture was evacuated. When the pressure dropped to ≤-0.09 MPa, the mixture was heated to 85° C., and a toluene solution of intermediate (III) was added dropwise, wherein 597.84 g (1.45 mol) of intermediate (III) was added, and the mixture was reacted for 7 hours to obtain a reaction solution containing intermediate (IV);
[0040] (5) The reaction solution containing the intermediate (IV) was decompressed to completely remove toluene, and the concentrated solution was dissolved in 2436 mL of tetrahydrofuran, stirred evenly, and 3045 mL of a 1 M tetrabutylammonium fluoride tetrahydrofuran solution (3.045 mol) was added, and the mixture was stirred and heated to 35° C. and reacted for 2 hours to obtain a reaction solution containing monoricinoleylglycerol;
[0041] (6) The reaction solution containing ricinoleyl glyceride was concentrated under reduced pressure to completely remove tetrahydrofuran, dissolved in 162 mL of a 10 / 1 volume ratio of n-hexane / ethyl acetate mixture, passed through a 100-200 mesh silica gel column, eluted with a mobile phase of n-hexane / ethyl acetate in a volume ratio of 8 / 1, applied to a TLC plate, the developing solvent of the TLC plate was n-hexane / ethyl acetate in a volume ratio of 5 / 1, the eluate containing ricinoleyl glyceride was collected, and concentrated under reduced pressure to completely remove the n-hexane / ethyl acetate to obtain a concentrated solution;
[0042] (7) Passing the concentrated solution obtained in step (6) into a storage tank of a secondary molecular distillation device; setting the temperature of the secondary molecular distillation device to 190° C., and when the vacuum degree drops below 5 Pa, passing the filtrate into the cavity of the secondary molecular distillation device at a flow rate of 60 ml / min for molecular distillation, and collecting the heavy components to obtain medicinal monoricinoleyl glyceride (V).
[0043] The synthetic route is as follows:
[0044]
[0045] The TBSCl is the abbreviation of tert-butyldimethylchlorosilane; the OTBS is the abbreviation of tert-butyldimethylsiloxy; and the TBAF is the abbreviation of tetrabutylammonium fluoride.
[0046] After sampling and testing, the product is qualified and then packaged and stored. Figure 1 and Figure 2 ) 506.23g, purification yield 84.93%. After inspection, the quality indicators all meet the pharmacopoeia standards, see Table 1.
[0047] Example 2
[0048] The preparation method of medicinal monoricinoleyl glyceride comprises the following steps:
[0049] (1) 500 g (1.6 mol) of ricinoleic acid methyl ester, 4000 g of dichloromethane, and 200 g of triethylamine were added to a reaction vessel in sequence, and stirred evenly under a nitrogen atmosphere; the temperature was lowered to 0° C., and a 7 M dichloromethane solution (366 mL, 2.56 mol) of tert-butyldimethylsilyl chloride was added dropwise under stirring, and the temperature was raised to 40° C. and reacted for 3 hours to obtain a reaction solution containing the intermediate (II);
[0050] (2) The reaction solution containing the intermediate (II) was filtered, and the filtrate was concentrated under reduced pressure until the mass of the concentrate was 4 times the mass of ricinoleic acid methyl ester (2000 g), and passed through a 100-200 mesh silica gel column, eluted with dichloromethane / methanol in a volume ratio of 10 / 1 as the mobile phase, and spotted on a TLC plate, the developing solvent of the TLC plate was dichloromethane / methanol in a volume ratio of 6 / 1, and the eluate containing the intermediate (II) was collected, and the eluate was concentrated under reduced pressure and dried to obtain 656.44 g of the intermediate (II);
[0051] (3) 656.44 g (1.54 mol) of intermediate (II) was dissolved in 1969.3 g of methanol, 3080 mL of 1 M sodium hydroxide aqueous solution was added, the temperature was raised to 40° C., and the reaction was carried out for 4 hours to obtain a sodium salt reaction solution containing intermediate (III). The methanol was removed by concentration under reduced pressure, the pH was adjusted to 7.0 with dilute hydrochloric acid, 1312.9 g of dichloromethane was added for extraction, the dichloromethane extract was collected and concentrated, and dried to obtain 601.27 g (1.46 mol) of intermediate (III);
[0052] (4) 141.0 g (1.53 mol) of glycerol and 846.2 g of toluene were sequentially added to a reaction vessel equipped with a water separator, and 4.81 g of anhydrous p-toluenesulfonic acid was added. The reaction was evacuated until the pressure dropped to ≤-0.09 MPa, the temperature was raised to 110° C., and a toluene solution of the intermediate (III) was added dropwise, wherein the intermediate (III) was 601.27 g (1.46 mol). The reaction was carried out for 4 hours to obtain a reaction solution containing the intermediate (IV);
[0053] (5) The reaction solution containing the intermediate (IV) was decompressed to completely remove toluene, and the concentrated solution was dissolved in 2274 mL of tetrahydrofuran, stirred evenly, and 1895 mL of a 1 M tetrabutylammonium fluoride tetrahydrofuran solution (1.895 mol) was added, and the mixture was stirred and heated to 25° C. and reacted for 4 hours to obtain a reaction solution containing monoricinoleylglycerol;
[0054] (6) The reaction solution containing ricinoleyl glyceride was concentrated under reduced pressure to completely remove tetrahydrofuran, dissolved in 227 mL of a 10 / 1 volume ratio of n-hexane / ethyl acetate mixture, passed through a 100-200 mesh silica gel column, eluted with a mobile phase of n-hexane / ethyl acetate in a volume ratio of 8 / 1, applied to a TLC plate, the developing solvent of the TLC plate was n-hexane / ethyl acetate in a volume ratio of 5 / 1, the eluate containing ricinoleyl glyceride was collected, and concentrated under reduced pressure to completely remove the n-hexane / ethyl acetate to obtain a concentrated solution;
[0055] (7) Passing the concentrated solution obtained in step (6) into a storage tank of a secondary molecular distillation device; setting the temperature of the secondary molecular distillation device to 145° C., and when the vacuum degree drops below 5 Pa, passing the filtrate into the cavity of the secondary molecular distillation device at a flow rate of 25 ml / min for molecular distillation, and collecting the heavy components to obtain medicinal monoricinoleic acid glyceride (V).
[0056] After sampling and testing, the product was qualified and then packaged and stored. 510.64g of medicinal monoricinoleic acid glyceride, purification yield 85.67%. After inspection, the quality indicators all met the pharmacopoeia standards, see Table 1.
[0057] Example 3
[0058] The preparation method of medicinal monoricinoleyl glyceride comprises the following steps:
[0059] (1) 500 g (1.6 mol) of methyl ricinoleate, 3500 g of dichloromethane, and 250 g of triethylamine were added to a reaction vessel in sequence, and stirred evenly under a nitrogen atmosphere; the temperature was lowered to 0° C., and a 7 M dichloromethane solution (320 mL, 2.24 mol) of tert-butyldimethylsilyl chloride was added dropwise under stirring, and the temperature was raised to 35° C. and reacted for 3.5 hours to obtain a reaction solution containing the intermediate (II);
[0060] (2) The reaction solution containing the intermediate (II) was filtered, and the filtrate was concentrated under reduced pressure until the mass of the concentrate was 3 times the mass of ricinoleic acid methyl ester (1500 g), and passed through a 100-200 mesh silica gel column, eluted with dichloromethane / methanol in a volume ratio of 10 / 1 as the mobile phase, and spotted on a TLC plate, the developing solvent of the TLC plate was dichloromethane / methanol in a volume ratio of 6 / 1, and the eluate containing the intermediate (II) was collected, and the eluate was concentrated under reduced pressure and dried to obtain 641.97 g of the intermediate (II);
[0061] (3) 641.97 g (1.51 mol) of intermediate (II) was dissolved in 3209.9 g of methanol, 2260 mL of 1 M sodium hydroxide aqueous solution was added, the temperature was raised to 50° C., and the reaction was carried out for 3 hours to obtain a sodium salt reaction solution containing intermediate (III). The methanol was removed by concentration under reduced pressure, the pH was adjusted to 6.8 with dilute hydrochloric acid, 2567.9 g of dichloromethane was added for extraction, the dichloromethane extract was collected and concentrated, and dried to obtain 604.58 g (1.47 mol) of intermediate (III);
[0062] (4) 202.4 g (2.2 mol) of glycerol and 910.8 g of toluene were sequentially added to a reaction vessel equipped with a water separator, and 9.07 g of T-62MP strong acid cation exchange resin was added. The mixture was evacuated until the pressure dropped to ≤-0.09 MPa, and the temperature was raised to 100° C. The toluene solution of intermediate (III) (604.58 g (1.47 mol) of intermediate (III) was added dropwise. The reaction was carried out for 5 hours to obtain a reaction solution containing intermediate (IV);
[0063] (5) The reaction solution containing the intermediate (IV) was decompressed to completely remove toluene, and the concentrated solution was dissolved in 2790 mL of tetrahydrofuran, stirred evenly, and 2790 mL of a 1 M tetrabutylammonium fluoride tetrahydrofuran solution (2.79 mol) was added, stirred, heated to 30° C., and reacted for 3 hours to obtain a reaction solution containing monoricinoleyl glyceride;
[0064] (6) The reaction solution containing ricinoleyl monoglyceride was concentrated under reduced pressure to completely remove tetrahydrofuran, dissolved in 215 mL of a 10 / 1 volume ratio of n-hexane / ethyl acetate mixture, passed through a 100-200 mesh silica gel column, eluted with a mobile phase of n-hexane / ethyl acetate in a volume ratio of 8 / 1, applied to a TLC plate, the developing solvent of the TLC plate was n-hexane / ethyl acetate in a volume ratio of 5 / 1, the eluate containing ricinoleyl monoglyceride was collected, and concentrated under reduced pressure to completely remove the n-hexane / ethyl acetate to obtain a concentrated solution;
[0065] (7) Passing the concentrated solution obtained in step (6) into a storage tank of a secondary molecular distillation device; setting the temperature of the secondary molecular distillation device to 180° C., and when the vacuum degree drops below 5 Pa, passing the filtrate into the cavity of the secondary molecular distillation device at a flow rate of 35 ml / min for molecular distillation, and collecting the heavy components to obtain medicinal monoricinoleic acid glyceride (V).
[0066] After sampling and testing, the product was qualified and then packaged and stored. 514.46g of medicinal monoricinoleic acid glyceride was obtained, and the purification yield was 86.31%. After inspection, the quality indicators all met the pharmacopoeia standards, as shown in Table 1.
[0067] Example 4
[0068] The preparation method of medicinal monoricinoleyl glyceride comprises the following steps:
[0069] (1) 500 g (1.6 mol) of methyl ricinoleate, 3750 g of dichloromethane, and 300 g of triethylamine were added to a reaction vessel in sequence, and stirred evenly under a nitrogen atmosphere; the temperature was lowered to 0° C., and a 7 M dichloromethane solution (286 mL, 2.0 mol) of tert-butyldimethylsilyl chloride was added dropwise under stirring; the temperature was raised to 30° C., and the reaction was carried out for 4 hours to obtain a reaction solution containing the intermediate (II);
[0070] (2) The reaction solution containing the intermediate (II) was filtered, and the filtrate was concentrated under reduced pressure until the mass of the concentrate was 3.5 times the mass of ricinoleic acid methyl ester (1750 g), and passed through a 100-200 mesh silica gel column, eluted with dichloromethane / methanol in a volume ratio of 10 / 1 as the mobile phase, and spotted on a TLC plate, the developing solvent of the TLC plate was dichloromethane / methanol in a volume ratio of 6 / 1, and the eluate containing the intermediate (II) was collected, and the eluate was concentrated under reduced pressure and dried to obtain 647.23 g of the intermediate (II);
[0071] (3) 647.23 g (1.52 mol) of intermediate (II) was dissolved in 2588.9 g of methanol, 2733 mL of 1 M sodium hydroxide aqueous solution was added, the temperature was raised to 40° C., and the reaction was carried out for 4 hours to obtain a sodium salt reaction solution containing intermediate (III). The methanol was removed by concentration under reduced pressure, the pH was adjusted to 6.6 with dilute hydrochloric acid, 1941.7 g of dichloromethane was added for extraction, the dichloromethane extract was collected and concentrated, and dried to obtain 610.94 g (1.48 mol) of intermediate (III);
[0072] (4) 163.76 g (1.78 mol) of glycerol and 900.7 g of toluene were sequentially added to a reaction vessel equipped with a water separator, and 6.11 g of anhydrous p-toluenesulfonic acid was added. The reaction was evacuated until the pressure dropped to ≤-0.09 MPa, the temperature was raised to 90° C., and a toluene solution of the intermediate (III) was added dropwise, wherein the intermediate (III) was 610.94 g (1.48 mol). The reaction was carried out for 6.5 hours to obtain a reaction solution containing the intermediate (IV);
[0073] (5) The reaction solution containing the intermediate (IV) was decompressed to completely remove toluene, and the concentrated solution was dissolved in 1998 mL of tetrahydrofuran, stirred evenly, and 2220 mL of a 1 M tetrabutylammonium fluoride tetrahydrofuran solution (2.22 mol) was added, and the mixture was stirred and heated to 25° C. and reacted for 4 hours to obtain a reaction solution containing monoricinoleylglycerol;
[0074] (6) The reaction solution containing ricinoleyl glyceride was concentrated under reduced pressure to completely remove tetrahydrofuran, dissolved in 167 mL of a 10 / 1 volume ratio of n-hexane / ethyl acetate mixture, passed through a 100-200 mesh silica gel column, eluted with a mobile phase of n-hexane / ethyl acetate in a volume ratio of 8 / 1, applied to a TLC plate, the developing solvent of the TLC plate was n-hexane / ethyl acetate in a volume ratio of 5 / 1, the eluate containing ricinoleyl glyceride was collected, and concentrated under reduced pressure to completely remove the n-hexane / ethyl acetate to obtain a concentrated solution;
[0075] (7) Passing the concentrated solution obtained in step (6) into a storage tank of a secondary molecular distillation device; setting the temperature of the secondary molecular distillation device to 160° C., and when the vacuum degree drops below 5 Pa, passing the filtrate into the cavity of the secondary molecular distillation device at a flow rate of 45 ml / min for molecular distillation, and collecting the heavy components to obtain medicinal monoricinoleyl glyceride (V).
[0076] After sampling and testing, the product was qualified and then packaged and stored. 513.68g of medicinal monoricinoleic acid glyceride, purification yield 86.18%. After inspection, the quality indicators all met the pharmacopoeia standards, see Table 1.
[0077] Example 5
[0078] The preparation method of medicinal monoricinoleyl glyceride comprises the following steps:
[0079] (1) 500 g (1.6 mol) of methyl ricinoleate, 3500 g of dichloromethane, and 275 g of triethylamine were added to a reaction vessel in sequence, and stirred evenly under a nitrogen atmosphere; the temperature was lowered to 0° C., and a 7 M dichloromethane solution (297 mL, 2.08 mol) of tert-butyldimethylsilyl chloride was added dropwise under stirring, and the temperature was raised to 25° C. and reacted for 5 hours to obtain a reaction solution containing the intermediate (II);
[0080] (2) The reaction solution containing the intermediate (II) was filtered, and the filtrate was concentrated under reduced pressure until the mass of the concentrate was 3.2 times the mass of ricinoleic acid methyl ester (1600 g), and passed through a 100-200 mesh silica gel column, eluted with dichloromethane / methanol in a volume ratio of 10 / 1 as the mobile phase, and spotted on a TLC plate, the developing solvent of the TLC plate was dichloromethane / methanol in a volume ratio of 6 / 1, and the eluate containing the intermediate (II) was collected, and the eluate was concentrated under reduced pressure and dried to obtain 653.18 g of the intermediate (II);
[0081] (3) 653.18 g (1.53 mol) of intermediate (II) was dissolved in 3919.1 g of methanol, 2450 mL of 1 M sodium hydroxide aqueous solution was added, the temperature was raised to 55° C., and the reaction was carried out for 2.5 hours to obtain a sodium salt reaction solution containing intermediate (III). The reaction solution was concentrated under reduced pressure to remove methanol, the pH was adjusted to 6.7 with dilute hydrochloric acid, 2286 g of dichloromethane was added for extraction, and the dichloromethane extract was collected and concentrated to obtain 618.24 g (1.50 mol) of intermediate (III);
[0082] (4) 193.13 g (2.10 mol) of glycerol and 772.5 g of toluene were sequentially added to a reaction vessel equipped with a water separator, and 6.18 g of solid acid catalyst No. 4 was added. The mixture was evacuated until the pressure dropped to ≤-0.09 MPa, the temperature was raised to 95° C., and a toluene solution of intermediate (III) (618.24 g (1.50 mol) of intermediate (III) was added dropwise. The reaction was carried out for 6 hours to obtain a reaction solution containing intermediate (IV);
[0083] (5) The reaction solution containing the intermediate (IV) was decompressed to completely remove toluene, and the concentrated solution was dissolved in 2805 mL of tetrahydrofuran, stirred evenly, and 2550 mL of a 1 M tetrabutylammonium fluoride tetrahydrofuran solution (2.55 mol) was added, and the mixture was stirred and heated to 35° C. and reacted for 2 hours to obtain a reaction solution containing monoricinoleylglycerol;
[0084] (6) The reaction solution containing ricinoleyl glyceride was concentrated under reduced pressure to completely remove tetrahydrofuran, dissolved in 200 mL of a 10 / 1 volume ratio of n-hexane / ethyl acetate mixture, passed through a 100-200 mesh silica gel column, eluted with a mobile phase of n-hexane / ethyl acetate in a volume ratio of 8 / 1, applied to a TLC plate, the developing solvent of the TLC plate was n-hexane / ethyl acetate in a volume ratio of 5 / 1, the eluate containing ricinoleyl glyceride was collected, and concentrated under reduced pressure to completely remove the n-hexane / ethyl acetate to obtain a concentrated solution;
[0085] (7) Passing the concentrated solution obtained in step (6) into a storage tank of a secondary molecular distillation device; setting the temperature of the secondary molecular distillation device to 170° C., and when the vacuum degree drops below 5 Pa, passing the filtrate into the cavity of the secondary molecular distillation device at a flow rate of 50 ml / min for molecular distillation, and collecting the heavy components to obtain medicinal monoricinoleyl glyceride (V).
[0086] After sampling and testing, the product was qualified and then packaged and stored. 515.95g of medicinal monoricinoleic acid glyceride, purification yield 86.56%. After inspection, the quality indicators all met the pharmacopoeia standards, see Table 1.
[0087] Table 1 Pharmaceutical enterprise standards and test results of monoricinoleylglycerol
[0088]
Claims
1. A method for preparing medicinal monoricinoleyl glyceride, Its characteristics are The following steps are involved: (1) methyl ricinoleate (I), dichloromethane and triethylamine are added to a reaction vessel in a mass ratio of 1:6.5-8:0.4-0.7, and stirred evenly under a nitrogen atmosphere; the temperature is lowered to 0° C., and a 7M dichloromethane solution of tert-butyldimethylsilyl chloride is added dropwise under stirring, the temperature is raised to 25-40° C., and the reaction is carried out for 3-5 hours to obtain a reaction solution containing the intermediate (II), wherein the molar ratio of methyl ricinoleate to tert-butyldimethylsilyl chloride is 1:1.1-1.6; (2) filtering the reaction solution containing the intermediate (II), concentrating the filtrate under reduced pressure until the mass of the concentrate is 2.5 to 4 times the mass of ricinoleic acid methyl ester, passing through a 100 to 200 mesh silica gel column, eluting with dichloromethane / methanol in a volume ratio of 10 / 1 as the mobile phase, spotting on a TLC plate, the developing solvent of the TLC plate being dichloromethane / methanol in a volume ratio of 6 / 1, collecting the eluate containing the intermediate (II), concentrating under reduced pressure, and drying to obtain the intermediate (II); (3) Dissolve the intermediate (II) in methanol, add a 1M sodium hydroxide aqueous solution, wherein the molar ratio of the intermediate (II) to the sodium hydroxide is 1:1.3-2.0; heat to 40-60°C, react for 2-4 hours to obtain a sodium salt reaction solution containing the intermediate (III), and concentrate under reduced pressure to remove methanol; adjust the pH to 6.5-7.0 with dilute hydrochloric acid, add dichloromethane for extraction, collect and concentrate the dichloromethane extract, and dry to obtain the intermediate (III); (4) adding glycerol and toluene in a mass ratio of 1:3.5-6 to a reaction vessel equipped with a water separator, adding a solid acid catalyst, evacuating the vessel, and heating the vessel until the pressure drops to ≤-0.09 MPa, adding a toluene solution of the intermediate (III) dropwise, and reacting the mixture for 4-7 hours to obtain a reaction solution containing the intermediate (IV), wherein the molar ratio of the intermediate (III) to glycerol is 1:1.05-1.7; (5) the reaction solution containing the intermediate (IV) is decompressed to completely remove toluene, the concentrated solution is dissolved in a tetrahydrofuran solvent, stirred evenly, a 1M tetrabutylammonium fluoride tetrahydrofuran solution is added, the temperature is raised to 25-35° C. with stirring, and the reaction is performed for 2-4 hours to obtain a reaction solution containing monoricinoleylglycerol, wherein the molar ratio of the tetrabutylammonium fluoride to the intermediate (III) is 1.3-2.1:1; and the volume of the tetrahydrofuran solvent is 0.8-1.2 times the volume of the 1M tetrabutylammonium fluoride tetrahydrofuran solution; (6) The reaction solution containing ricinoleyl glyceride is concentrated under reduced pressure to completely remove tetrahydrofuran, dissolved with a mixture of n-hexane / ethyl acetate in a volume ratio of 10 / 1, passed through a 100-200 mesh silica gel column, eluted with a mobile phase of n-hexane / ethyl acetate in a volume ratio of 8 / 1, applied to a TLC plate, wherein the developing solvent of the TLC plate is n-hexane / ethyl acetate in a volume ratio of 5 / 1, the eluate containing ricinoleyl glyceride is collected, and concentrated under reduced pressure to completely remove n-hexane / ethyl acetate to obtain a concentrated solution; the volume of the n-hexane / ethyl acetate mixture in a volume ratio of 10 / 1 is 1 / 15 to 1 / 10 of the volume of the tetrahydrofuran solvent described in step (5); (7) passing the concentrated solution obtained in step (6) into a storage tank of a secondary molecular distillation device; setting the temperature of the secondary molecular distillation device to 145° C. to 190° C., and when the vacuum degree drops below 5 Pa, passing the concentrated solution into the cavity of the secondary molecular distillation device at a flow rate of 25 mL / min to 60 mL / min, performing molecular distillation, and collecting the heavy components to obtain medicinal monoricinoleyl glyceride (V); The synthetic route is as follows: The TBSCl is the abbreviation of tert-butyldimethylchlorosilane; the OTBS is the abbreviation of tert-butyldimethylsiloxy; and the TBAF is the abbreviation of tetrabutylammonium fluoride.
2. The preparation method of the medicinal monoricinoleyl glyceride according to claim 1, Its characteristics are In the step (1), the molar ratio of methyl ricinoleate to tert-butyldimethylchlorosilane is 1:1.25-1.
4.
3. The preparation method of the medicinal monoricinoleyl glyceride according to claim 1, Its characteristics are The mass of the solid acid catalyst in step (4) is equivalent to 0.8% to 2.5% of the mass of the intermediate (III).
4. The method for preparing the medicinal monoricinoleylglycerol according to claim 1 or 3, Its characteristics are The solid acid catalyst is anhydrous p-toluenesulfonic acid, solid acid catalyst No. 4 or T-62MP strong acid cation exchange resin.
5. The preparation method of the medicinal monoricinoleyl glyceride according to claim 1, Its characteristics are The molar ratio of the intermediate (III) to glycerol in step (4) is 1:1.2-1.
5.
6. The preparation method of the medicinal monoricinoleyl glyceride according to claim 1, Its characteristics are The volume of the tetrahydrofuran solvent in step (5) is equal to the volume of a 1M tetrabutylammonium fluoride solution in tetrahydrofuran.
7. The preparation method of the medicinal monoricinoleyl glyceride according to claim 1, Its characteristics are The temperature of the secondary molecular distillation equipment in step (7) is set to 160°C to 180°C.
